vebecotutamab + lenvatinib

vebecotutamab + lenvatinib is a combination therapy being investigated for the treatment of salivary gland carcinoma. Vebecotutamab (MGD019) is a bispecific DART (Dual-Affinity Re-Targeting) molecule designed to simultaneously target and block the immune checkpoint receptors PD-1 and CTLA-4, thereby enhancing T-cell activation and anti-tumor immune responses. Lenvatinib is an oral multi-receptor tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR1-3), fibroblast growth factor receptors (FGFR1-4), platelet-derived growth factor receptor alpha (PDGFRα), KIT, and RET. By combining dual checkpoint blockade with anti-angiogenic and anti-proliferative kinase inhibition, this regimen aims to overcome tumor-induced immunosuppression and inhibit tumor growth and vascularization. It is currently being evaluated in a Phase 2 umbrella trial sponsored by Peking Union Medical College for patients with locally advanced, recurrent, or metastatic salivary gland carcinoma.

Brand names

Lenvima

Other names

MGD019 + lenvatinibvebecotutamab ± lenvatinib